News >

FDA Grants Fast Track Designation to CLR 131 for DLBCL

Lisa Astor
Published: Thursday, Jul 11, 2019

The FDA has granted a fast track designation to CLR 131 for use as a treatment for patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL).1

A fast track designation has already been granted to CLR 131 for the treatment of patients with relapsed/refractory multiple myeloma, and the agent also received an orphan drug designation for the treatment of pediatric patients with osteosarcoma.


  1. Cellectar Receives FDA Fast Track Designation for CLR 131 in Diffuse Large B-Cell Lymphoma [press release]. Florham Park, NJ: Cellectar Biosciences; July 9, 2019. Accessed July 9, 2019.
  2. Cellectar Reports Positive Phase 2 Interim Data for CLR 131 in Relapsed/Refractory DLBCL Patients [press release]. Florham Park, NJ: Cellectar Biosciences; July 18, 2018. Accessed July 9, 2019.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication